Skip to main content
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · SABS ISIN · US0891152086 US Manufacturing
Open in API
Filings indexed 398 across all filing types
Latest filing 2024-05-14 Director's Dealing
Country US United States of America
Listing US SABS

About SAB Biotherapeutics, Inc.

https://www.sab.bio/

SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a novel class of immunotherapies. The company's proprietary platform produces targeted, high-potency, fully human polyclonal antibodies without the need for human donors. This technology utilizes transgenic cattle to generate natural human antibodies in response to specific disease targets. The company's lead product candidate, SAB-142, is a disease-modifying immunotherapy being developed to delay the onset and progression of Type 1 Diabetes (T1D) by addressing the underlying autoimmune cause. SAB's development pipeline also includes programs targeting infectious diseases, such as severe influenza and antibiotic resistance.

Recent filings

Filing Released Lang Actions
3
Director's Dealing
2024-05-14 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 3, 2024, reporting the appointment of a new director to the company's board. The key section is Item 5.02, which specifically addresses the departure or appointment of directors or certain officers. There is no financial data or report content; rather, it is an announcement of a board management change. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 6392 characters, which is sufficient for a detailed announcement but does not contain financial statements or earnings data. Hence, the classification is MANG with high confidence.
2024-05-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. It reports a corporate update about the completion of dosing in a phase one trial and mentions a forthcoming press release. The document does not contain detailed financial statements or comprehensive financial analysis, nor is it an earnings release or annual/interim report. It is a regulatory announcement of a material event or corporate update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-04-15 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates. The text specifically mentions that the company issued a press release announcing financial results for the year and quarter ended December 31, 2023, and that the press release is furnished as an exhibit. The document itself does not contain the full financial results or detailed financial statements but rather references the press release. The length of the document is 3825 characters, which is relatively short and consistent with a current report filing that includes a press release. According to the classification rules, a Form 8-K announcing financial results and including a press release is best classified as an Earnings Release (ER) since it is the initial announcement of quarterly/periodical financial results with key highlights only, not the full annual or quarterly report. Therefore, the appropriate classification is ER with high confidence.
2024-03-29 English
10-K
Annual Report FY 2023
2024-03-28 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 5, 2024, by SAB Biotherapeutics, Inc. It reports the entry into material definitive agreements, specifically executive employment agreements for the President and COO. The content focuses on management changes and employment contracts rather than financial results, audit information, or other report types. The key section is Item 5.02, which deals with departure, election, or appointment of directors or officers. This aligns with the category for Board/Management Information (MANG). The document length is 6627 characters, which is sufficient to contain substantive information rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2024-03-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.